Blurbs

Teva Pharmaceutical Industries Ltd (TEVA): Thanks for the Cuts But Where Is the Revenue Guidance?

Mizuho’s Irina Rivkind reflects on how much Teva’s cost cutting compare to expectations; The missing puzzle piece – revenue guidance.

Valeant Pharmaceuticals Intl Inc (VRX) Bear Boosts Price Target Amid Solid Turnaround Efforts

Mizuho’s Irina Rivkind Koffler cannot “justify” changing her rating on Valeant. Instead, the analyst lifts her price target by 40%; Here’s why.

Walt Disney (DIS) Aims to Win the Race for Premium Content

Canaccord’s Aravinda Galappatthige weighs in on the greater implications in a post-Disney/Fox merger.

Trading Cable Heading into the New Year

The GBP/USD currency pair is holding at the critical 1.34 level.

Veeva Systems Is Worth the Buy Longer-Term, Says Canaccord

While Veeva Systems (NYSE:VEEV) shares are dipping close to 7% after a print that failed to impress the Street, Canaccord’s┬áRichard Davis highlights enticing …

This Analyst Finds Nutanix Well-Positioned in the Enterprise Market Following Raymond James Tech Conference

After Nutanix Inc (NASDAQ:NTNX) CFO Duston Williams discussed the company’s transition to software taking center stage for the business at the annual Raymond …

Does Helios and Matheson Analytics’ Selloff Represents a Buying Opportunity?

Helios and Matheson Analytics (NASDAQ:HMNY) is an IT consulting company — but one with a twist. Helios, you see, owns a majority stake …

Guggenheim Storms Into the Dermatology Space; Initiates Buy on Revance Therapeutics, Inc. (RVNC)

Guggenheim analyst Rohit Vanjani has initiated coverage of the dermatology space, announcing ratings on four pharmaceuticals stocks. We don’t have time to cover …